Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss

M. J. Everly, J. J. Everly, Lois J Arend, P. Brailey, B. Susskind, A. Govil, A. Rike, P. Roy-Chaudhury, G. Mogilishetty, R. R. Alloway, A. Tevar, E. S. Woodle

Research output: Contribution to journalArticle

Abstract

The effect of de novo DSA detected at the time of acute cellular rejection (ACR) and the response of DSA levels to rejection therapy on renal allograft survival were analyzed. Kidney transplant patients with acute rejection underwent DSA testing at rejection diagnosis with DSA levels quantified using Luminex single-antigen beads. Fifty-two patients experienced acute rejection with 16 (31%) testing positive for de novo DSA. Median follow-up was 27.0 ± 17.4 months postacute rejection. Univariate analysis of factors influencing allograft survival demonstrated significance for African American race, DGF, cytotoxic PRA >20% (current) and/or >50% (peak), de novo DSA, C4d and repeat transplantation. Multivariate analysis showed only de novo DSA (6.6-fold increased allograft loss risk, p = 0.017) to be significant. Four-year allograft survival was higher with ACR (without DSA) (100%) than mixed acute rejection (ACR with DSA/C4d) (65%) or antibody-mediated rejection (35%) (p <0.001). Patients with >50% reduction in DSA within 14 days experienced higher allograft survival (p = 0.039). De novo DSAs detected at rejection are associated with reduced allograft survival, but prompt DSA reduction was associated with improved allograft survival. DSA should be considered a potential new end point for rejection therapy.

Original languageEnglish (US)
Pages (from-to)1063-1071
Number of pages9
JournalAmerican Journal of Transplantation
Volume9
Issue number5
DOIs
StatePublished - May 2009

Fingerprint

Allografts
Tissue Donors
Kidney
Antibodies
African Americans
Statistical Factor Analysis
Multivariate Analysis
Transplantation
Transplants
Antigens
Therapeutics

Keywords

  • Allograft survival
  • Antibody-mediated rejection
  • Antihumoral therapy
  • C4d
  • Donor-specific antibodies
  • Mixed acute rejection

ASJC Scopus subject areas

  • Transplantation
  • Immunology and Allergy
  • Pharmacology (medical)

Cite this

Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. / Everly, M. J.; Everly, J. J.; Arend, Lois J; Brailey, P.; Susskind, B.; Govil, A.; Rike, A.; Roy-Chaudhury, P.; Mogilishetty, G.; Alloway, R. R.; Tevar, A.; Woodle, E. S.

In: American Journal of Transplantation, Vol. 9, No. 5, 05.2009, p. 1063-1071.

Research output: Contribution to journalArticle

Everly, MJ, Everly, JJ, Arend, LJ, Brailey, P, Susskind, B, Govil, A, Rike, A, Roy-Chaudhury, P, Mogilishetty, G, Alloway, RR, Tevar, A & Woodle, ES 2009, 'Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss', American Journal of Transplantation, vol. 9, no. 5, pp. 1063-1071. https://doi.org/10.1111/j.1600-6143.2009.02577.x
Everly, M. J. ; Everly, J. J. ; Arend, Lois J ; Brailey, P. ; Susskind, B. ; Govil, A. ; Rike, A. ; Roy-Chaudhury, P. ; Mogilishetty, G. ; Alloway, R. R. ; Tevar, A. ; Woodle, E. S. / Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. In: American Journal of Transplantation. 2009 ; Vol. 9, No. 5. pp. 1063-1071.
@article{e39bd5ec498541668986f27475c5d190,
title = "Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss",
abstract = "The effect of de novo DSA detected at the time of acute cellular rejection (ACR) and the response of DSA levels to rejection therapy on renal allograft survival were analyzed. Kidney transplant patients with acute rejection underwent DSA testing at rejection diagnosis with DSA levels quantified using Luminex single-antigen beads. Fifty-two patients experienced acute rejection with 16 (31{\%}) testing positive for de novo DSA. Median follow-up was 27.0 ± 17.4 months postacute rejection. Univariate analysis of factors influencing allograft survival demonstrated significance for African American race, DGF, cytotoxic PRA >20{\%} (current) and/or >50{\%} (peak), de novo DSA, C4d and repeat transplantation. Multivariate analysis showed only de novo DSA (6.6-fold increased allograft loss risk, p = 0.017) to be significant. Four-year allograft survival was higher with ACR (without DSA) (100{\%}) than mixed acute rejection (ACR with DSA/C4d) (65{\%}) or antibody-mediated rejection (35{\%}) (p <0.001). Patients with >50{\%} reduction in DSA within 14 days experienced higher allograft survival (p = 0.039). De novo DSAs detected at rejection are associated with reduced allograft survival, but prompt DSA reduction was associated with improved allograft survival. DSA should be considered a potential new end point for rejection therapy.",
keywords = "Allograft survival, Antibody-mediated rejection, Antihumoral therapy, C4d, Donor-specific antibodies, Mixed acute rejection",
author = "Everly, {M. J.} and Everly, {J. J.} and Arend, {Lois J} and P. Brailey and B. Susskind and A. Govil and A. Rike and P. Roy-Chaudhury and G. Mogilishetty and Alloway, {R. R.} and A. Tevar and Woodle, {E. S.}",
year = "2009",
month = "5",
doi = "10.1111/j.1600-6143.2009.02577.x",
language = "English (US)",
volume = "9",
pages = "1063--1071",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss

AU - Everly, M. J.

AU - Everly, J. J.

AU - Arend, Lois J

AU - Brailey, P.

AU - Susskind, B.

AU - Govil, A.

AU - Rike, A.

AU - Roy-Chaudhury, P.

AU - Mogilishetty, G.

AU - Alloway, R. R.

AU - Tevar, A.

AU - Woodle, E. S.

PY - 2009/5

Y1 - 2009/5

N2 - The effect of de novo DSA detected at the time of acute cellular rejection (ACR) and the response of DSA levels to rejection therapy on renal allograft survival were analyzed. Kidney transplant patients with acute rejection underwent DSA testing at rejection diagnosis with DSA levels quantified using Luminex single-antigen beads. Fifty-two patients experienced acute rejection with 16 (31%) testing positive for de novo DSA. Median follow-up was 27.0 ± 17.4 months postacute rejection. Univariate analysis of factors influencing allograft survival demonstrated significance for African American race, DGF, cytotoxic PRA >20% (current) and/or >50% (peak), de novo DSA, C4d and repeat transplantation. Multivariate analysis showed only de novo DSA (6.6-fold increased allograft loss risk, p = 0.017) to be significant. Four-year allograft survival was higher with ACR (without DSA) (100%) than mixed acute rejection (ACR with DSA/C4d) (65%) or antibody-mediated rejection (35%) (p <0.001). Patients with >50% reduction in DSA within 14 days experienced higher allograft survival (p = 0.039). De novo DSAs detected at rejection are associated with reduced allograft survival, but prompt DSA reduction was associated with improved allograft survival. DSA should be considered a potential new end point for rejection therapy.

AB - The effect of de novo DSA detected at the time of acute cellular rejection (ACR) and the response of DSA levels to rejection therapy on renal allograft survival were analyzed. Kidney transplant patients with acute rejection underwent DSA testing at rejection diagnosis with DSA levels quantified using Luminex single-antigen beads. Fifty-two patients experienced acute rejection with 16 (31%) testing positive for de novo DSA. Median follow-up was 27.0 ± 17.4 months postacute rejection. Univariate analysis of factors influencing allograft survival demonstrated significance for African American race, DGF, cytotoxic PRA >20% (current) and/or >50% (peak), de novo DSA, C4d and repeat transplantation. Multivariate analysis showed only de novo DSA (6.6-fold increased allograft loss risk, p = 0.017) to be significant. Four-year allograft survival was higher with ACR (without DSA) (100%) than mixed acute rejection (ACR with DSA/C4d) (65%) or antibody-mediated rejection (35%) (p <0.001). Patients with >50% reduction in DSA within 14 days experienced higher allograft survival (p = 0.039). De novo DSAs detected at rejection are associated with reduced allograft survival, but prompt DSA reduction was associated with improved allograft survival. DSA should be considered a potential new end point for rejection therapy.

KW - Allograft survival

KW - Antibody-mediated rejection

KW - Antihumoral therapy

KW - C4d

KW - Donor-specific antibodies

KW - Mixed acute rejection

UR - http://www.scopus.com/inward/record.url?scp=65249160252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65249160252&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2009.02577.x

DO - 10.1111/j.1600-6143.2009.02577.x

M3 - Article

C2 - 19344434

AN - SCOPUS:65249160252

VL - 9

SP - 1063

EP - 1071

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 5

ER -